News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QT 5, Inc. Adds Leading Scientist To Medical Advisory Team


10/19/2005 5:10:45 PM

WESTLAKE VILLAGE, Calif, Nov. 13 /PRNewswire-FirstCall/ -- QT 5, Inc. (BULLETIN BOARD: QTFV) , manufacturer, distributor and marketers of biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula, today announced it has successfully recruited Donald V. Cramer, D.V.M., Ph.D. to join the Company's Medical Advisory Board. CEO, Timothy Owens said, "This is a great addition to an already impressive team of medical professionals. Dr. Cramer is renowned in the immunological and biological sciences. He is extremely talented and a powerful influence in all of the disciplines that are vital to our diagnostic products. He is especially well versed in Biological Threat Management and has many established relationships with the NIH (National Institute of Health). He will play a key role in maximizing the efficiency of our product positioning and process development. In fact, we have already benefited from Dr. Cramer's participation and his enthusiasm further convinces me of the potential of our products and the strength of our strategies."

Donald V. Cramer, D.V.M., Ph.D.

Dr. Cramer brings to QT5, Inc. his background as a distinguished scientist and consultant in biomedical sciences. He is an internationally recognized scientist in the areas of transplantation biology, immunology and pathology. Dr. Cramer has held academic appointments as Professor of Research, Keck School of Medicine, University of Southern California, and Associate Professor of Pathology with tenure at the University of Pittsburgh School of Medicine. Dr. Cramer received his D.V.M. degree from the University of California at Davis in 1966, a Ph.D in Experimental pathology from Harvard University, Cambridge, Massachusetts, in 1978. Dr. Cramer is a Diplomat of the American College of Veterinary Pathologists and conducted federally and privately funded research programs in immunogenetics, immunopathology and transplantation biology since 1971. He has published more than 300 articles, chapters and books in basic research and is recognized as a leading investigator in the use of xenografts for human transplantation.

In addition to his scientific accomplishments Dr. Cramer has served as the Director of Scientific Research in the Department of Surgery at Cedars-Sinai Medical Center, and the Department of Cardiothoracic Surgery, University of Southern California and member of many scientific advisory committees, including the Comparative Medicine Review Committee, National Center for Research Resources at the National Institutes of Health, and Secretary- Treasurer of the International Xenotransplantation Association. Dr. Cramer has served as Scientific Advisor to several biotechnology companies for the evaluation and development of medical technologies including Exten Industries, Ximerics, Inc., Apoimmune, Inc., Xenogenics, and Chief Scientific Officer, Molecular Express, Inc. Dr. Cramer brings to QT5, Inc. a background scientific expertise and business experience in the development of new medical technologies for application in the treatment of a wide variety of medically important diseases.

Dr. Leonard Makowka, MD. PhD.

Dr. Leonard Makowka leads the QT 5 advisory board as Senior Medical Research Advisor. He is a distinguished clinical surgeon, transplantation surgeon and medical researcher and is recognized as one of the World's leading authorities in hepatic science (study relating to the liver). From 1995 to 1997, Dr. Makowka was the Executive Director of the Comprehensive Liver Disease and Treatment Center and Director of the Liver Transplant Program at St. Vincent's Medical Center in Los Angeles, CA. Between 1989 and 1995, Dr. Makowka was the Chairman of the Department of Surgery and the Director of Transplantation Services at Cedars-Sinai Medical Center in Los Angeles, CA. He was also Professor of Surgery at the UCLA School of Medicine. Dr. Makowka trained under Dr. Thomas Starzl, the pioneer of liver transplantation, and was appointed Associated Professor in the Department of Surgery at the University of Pittsburgh. In 1982, Dr. Makowka began his residency at the University of Toronto, where in his final year he was appointed Chief Resident of Surgery. Dr. Makowka has performed hundreds of hepatobiliary and liver transplant procedures. Dr. Makowka received his M.D. degree from the University of Toronto Medical School in 1977, and Master of Science and Doctorate of Philosophy from the University of Toronto's Department of Pathology in 1979 and 1982. Dr. Makowka has published over 400 articles and chapters in both clinical and basic scientific research and continues to lecture worldwide.

Dr. Howard Wilner, MD

Dr. Howard Wilner has participated on the QT 5 Advisory Board as Senior Research Associate. He received his B.A. from Brooklyn College, and his M.D. from New York University School of Medicine. After Post Graduate Training in Internal Medicine, Nephrology, and Clinical Pharmacology and completion of Military Service, Dr. Wilner entered the private practice of medicine. He is Board Certified by the American Board of Internal Medicine as well as the Subspecialty Board of Nephrology. Dr. Wilner has had a distinguished career in medicine as both a Medical Executive and Practicing Physician. After serving as the Clinical Chief of Medicine at Cedars-Sinai Medical Center, he was the Executive Director of the Cedars-Sinai Comprehensive Cancer Center from 1988 through 1997. He remains on the Active Staff of the Hospital and in Private Practice.

Dr. Marcus Laux, ND

Dr. Marcus Laux currently serves as a Medical Research Advisor in the areas of Nutritional Science. He will also serve as Senior Associate Medical Research spokesman for the NICOWater product line. He is a leading authority on science-based natural medicines. Dr. Laux is a licensed naturopathic physician with over a decade of private family practice. He received his doctorate from National College of Naturopathic Medicine, Ptd, OR, where he serves as a clinical professor. Dr. Laux is a leading authority on science-based natural medicines, teaching continuing education seminars internationally for medical doctors and pharmacists. He is former Chief Science Officer for Nutrition for Life, Inc., and currently serves on several scientific Advisory Boards including Phytopharmic Enzymatic Therapy, and Unigen Pharmacia.

About QT 5, Inc.

QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: http://www.qt5inc.com/. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.

This press release contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause the results of QT 5, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by QT 5, Inc. with the Securities and Exchange Commission. QT 5, Inc. assumes no obligation and does not intend to update these forward-looking statements.

QT 5, Inc.

CONTACT: Steve Reder, President of QT 5, Inc., +1-818-338-1510,sreder@qt5inc.com; or Media - Peter Berk, +1-310-274-1072, ext. 205,peter@crierpr.com, or J.P. Lincoln, +1-310-274-1072, ext. 201, jp@crierpr.com,both of Crier Communications, for QT 5, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES